Marker Therapeutics, Inc.
MRKR
$1.43
$0.021.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.10M | 1.23M | 861.20K | 349.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.10M | 1.23M | 861.20K | 349.10K |
| Cost of Revenue | 2.84M | 2.14M | 2.35M | 4.18M | 3.14M |
| Gross Profit | -2.84M | -1.04M | -1.11M | -3.32M | -3.14M |
| SG&A Expenses | 1.23M | 846.60K | 1.02M | 945.20K | 1.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.07M | 2.99M | 3.37M | 5.12M | 4.50M |
| Operating Income | -4.07M | -1.88M | -2.14M | -4.26M | -4.50M |
| Income Before Tax | -3.18M | -1.72M | -2.00M | -4.02M | -4.45M |
| Income Tax Expenses | -- | -15.20K | -- | -- | -- |
| Earnings from Continuing Operations | -3.18M | -1.70M | -2.00M | -4.02M | -4.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.18M | -1.70M | -2.00M | -4.02M | -4.45M |
| EBIT | -4.07M | -1.88M | -2.14M | -4.26M | -4.50M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.16 | -0.09 | -0.12 | -0.29 | -0.40 |
| Normalized Basic EPS | -0.10 | -0.06 | -0.07 | -0.18 | -0.22 |
| EPS Diluted | -0.16 | -0.09 | -0.12 | -0.29 | -0.40 |
| Normalized Diluted EPS | -0.10 | -0.06 | -0.07 | -0.18 | -0.22 |
| Average Basic Shares Outstanding | 19.31M | 19.36M | 16.76M | 13.96M | 11.11M |
| Average Diluted Shares Outstanding | 19.31M | 19.36M | 16.76M | 13.96M | 11.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |